Proceedings of the National Academy of Sciences · 2014 · 162 citations · 45 references
Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyImmunotherapyAntigen RecognitionAntitumor T Cell ResponsesCancer ImmunotherapyCell-mediated ImmunityCytotoxic T Lymphocyte ResponsesTumor-associated AntigensAdaptive Antitumor ImmunityChronic Lymphocytic Leukemia TherapyHla-restricted T Cell RecognitionImmune Recognition ReceptorsT Cell-based ImmunotherapyT Cell-mediated Tumor ControlT-cell Responses To Tumor AntigensTumor Antigen Recognition
The breakthrough development of clinically effective immune checkpoint inhibitors illustrates the potential of T-cell-based immunotherapy to effectively treat malignancies. A remaining challenge is to increase and guide the specificities of anticancer immune responses, e.g., by therapeutic vaccination or by adoptive T-cell transfer. By analyzing the landscape of naturally presented HLA class I and II ligands of primary chronic lymphocytic leukemia (CLL), we delineated a novel category of tumor-associated T-cell antigens based on their exclusive and frequent representation in the HLA ligandome of leukemic cells. These antigens were validated across different stages and mutational subtypes of CLL and found to be robustly represented in HLA ligandomes of patients undergoing standard chemo-/immunotherapy. We demonstrate specific immune recognition of these antigens exclusively in CLL patients, with the frequencies of representation in CLL ligandomes correlating with the frequencies of immune recognition by patient T cells. Moreover, retrospective survival analysis revealed survival benefits for patients displaying immune responses to these antigens. These results directly imply these nonmutant self-peptides as pathophysiologically relevant tumor antigens and encourages their implementation for cancer immunotherapy.
45
KEGG: Kyoto Encyclopedia of Genes and Genomes
Minoru Kanehisa · Nucleic Acids Research · 2000 · 39.2K citations · Full text
KEGG: Kyoto Encyclopedia of Genes and Genomes
Hiroyuki Ogata, Susumu Goto, Kazushige Sato et al. · Nucleic Acids Research · 1999 · 32.4K citations · Full text
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17